체격과 체력과의 상관 관계에 관한 비교 연구

김서운(Kim Seo Woon) 한국여성체육학회 1988 한국여성체육학회지 Vol.2 No.-

I was study as comparative with to correlation of physique (height, weight, chest) and physical strength(100meter run, standing board jump, hang on crook arm, raise up upper body, throwing, 800meter long run) out of the body form main cause. It was produced result as following ; The main cause in physique (height, weight, chest) was showed so closely bound up with tall figure students, and 100 meter run and standing bound jump, two events from six-events physical strength cause, were only showed static interrelation. Besides among all : measure event in their physical strength bear no relation with each other.

신경회로망을 이용한 산업용 로봇의 역보정에 관한 연구

김휘동(Hwi-Dong Kim),서운학(Woon-Hak Seo),한성현(Sung-Hyun Han) 한국공작기계학회 1999 한국공작기계학회지 Vol.8 No.2

식도암 환자의 수술전 평가에서 기관지내시경의 역할

김봉석(Bong Seog Kim),김서운(Seo Woon Kim),이영현(Young Hyun Lee),조희준(Hee Jun Cho),이춘택(Choon Taek Lee),도영수(Young Soo Do),김효윤(Hyo Youn Kim),조재일(Jae Ill Zo),심영목(Young Mog Shim),이진오(JIn Oh Lee),강태웅(Tae Woong Kang 대한내과학회 1994 대한내과학회지 Vol.46 No.4

N/A Objective: For curative surgical treatment of esophageal cancer the resectability from the tracheobrochial tree would be the most important factor. Although CT scan has been used for the determination of the resectability of esophageal cancer, it has a limitation on the detection of esophageal cancer invasion to tracheobronchial tree We have performed flexible bronchoscopy in the patients with esophageal cancer to detect and classify the tracheobronchial tree alterations and to find the relation of bronchoscopic findings with the resectability. Method: From April 1990 to October 1992, 133 patients with esophageal cancer had received bronchoscopy. Bronchoscopic findings were classified into three groups: [Group I: normal, Group II: indirect effects (hyperemia and compression-mild, moderate, severe), group III: invasion). CT findings were a]so classified into three classes: [Class A: tumor separated from tracheobronehial tree, Class B: abutting tree, Class C: compressing tree]. We investigated the resectability of esophageal cancer according to bronchoscopic and CT findings. Results: 1) Among 133 patients, the bronchscopic findings were Group I in 41(30.8%), Group II in 66(49.6%), and Group III in 26(19.6%) patients. 2) Abnormal bronchoscopic findings were mainly found in trachea and left main bronchus and frequently found in upper and middle esophageal cancer patients, 3) The resection rate from tracheobronchial tree was 96.8% in group I and 75% in group II bronchoscopic finding. 4) The resections from tracheobronchial tree could be performed in 94.6% of Class A, in 70% of Class B and in 53.8% of Class C of CT scan patients. 5) Six of twelve unresectable patients belonged to Class C of CT scan finding If we excluded Class C in Group II patients, resectability would be increased to 87.5%. Conclusion: We could recommend the operation in esophgeal cancer patients with Group I and minimal Group II bronchoscopic finding. In advanced Group II and/or Class C of CT scan patients, neoadjuvant treatment and reevaluation could be recommended.

전이성 또는 재발성 식도암에 대한 Cisplatin , Etoposide 및 5 - Fluorouracil ( PEF ) 복합화학요법의 치료 효과

류백렬(Baek Yeol Ryoo),임영혁(Young Hyuck Im),강윤구(Yoon Koo Kang),정상훈(Sang Hoon Jeong),김현각(Hyun Kag Kim),이창희(Chang Hee Lee),윤종길(Jong Kil Yoon),천영국(Young Kug Cheon),김서운(Seo Woon Kim),김유철(You Cheoul Kim),김창민(C 대한내과학회 1996 대한내과학회지 Vol.51 No.4

N/A Esophageal cancer is widely disseminated in more than 80% of patients at the time of diagnosis and the prognosis of advanced esophageal cancer is dismal with a median survival of 5 to 8 months. Therefore, systemic chemotherapy has assumed an important role in the treatment of these patients. Among various combination chemotherapy regimens, the combination of cisplatin and 5-fluorouracil has been one of the most effective for esophageal cancer because of their synergism. Etoposide, although reported ineffective as a single agent, has been shown to be synergistic with cisplatin in vitro and in vivo. So, we conducted a phase 2 trial to evaluate the effect of a combination of cisplatin, etoposide and 5- FU (PEF) in patients with metastatic or recurrent esophageal cancer. Thirty-four patients with measurable lesion(s) received cisplatin (20㎎/㎡ i.v. Day 1~5), etoposide (100㎎/㎡ i.v. Day 1, 3 & 5) and 5-FU (800㎎/㎡ continuous i.v. for 12 hours, Day 1~5). Of 30 evaluable patients, 1(3.3%) had a complete response and 11(37%) had partial responses. The median duration of response was 29 weeks. The overall median survival was 34 weeks and the survival time in the responders was longer significantly than that of the non-responders. There was no significant prognostic factor influencing the response rate. Among total 135 cycles of chemotherapy, leukopenia was observed in 36% and thrombocytopenia in 4%. There was no treatment-related death. Main non-hematologic toxicities were neurotoxicity (17%), nephrotoxicity (3%), and stomatitis (10%) and diarrhea (10%). All the toxicities were mild and well tolerated. Conclusion: A combination chemotherapy of cisplatin, etoposide and 5-FU (PEF) was effective and well tolerated in patients with metastatic or recurrent esophageal cancer.

Alpha-Fetoprotein이 증가한 만성 간질환의 임상적 특성

김창민,홍석일,조희준,이영현,김봉석,홍원선,이진오,김유철,강태웅,김서운 대한소화기학회 1992 대한소화기학회지 Vol.24 No.4

In an attempt to investigate the factors influencing the specificity of serum level of alphafetoprotein (AFP) for hepatocellular carcinoma, serum levels of AFP were analyzed in 33 patients treated at the department of gastroenterology in the Korea Cancer Center Hospital between January 1989 and December 1991. All patients entered into the study had chronic liver disease with increased serum level of AFP, more than 50 ng/ml. Clinical and; laboratory parameters, such as HBsAg, Anti-HCV, GOT and GPT and image studies with ultraonograpy and computed tomography were sequentially evaluated, every two or three months, in 2Z' patients. Among 33 patients, 30 had liver cirrhosis and three had chronic hepatitis. The median level of serum AFP was 189 ng/ml in 33 patients. Thirty (90.9%) out of 33 patients were positive for HBsAg. Anti-HCV was tested in 14 patients, among whom four (28.6%) were positive. No significant correlation was observed between serum AFP levels and age, sex or positive rates for HBsAg, anti-HCV and cirrhosis. In 32 among 33 patients, no evidence of the development of hepatocellar carcinoma was found after the follow-up period of six to 36 months, when hepatocellar carcinoma teas diagnosed as the space occupying lesion in the liver by ultrasonograpy and computed tomography. Another one patient was also suggested not to develop hepatocellar carcinoma, when clinically evaluated, because liver function and serum AFP level were markedly improved. The follow-up period in 22 patients was determined as the period until the AFP level decreased below the cut-off value, 50 ng/ml, or the end of study period. The serum AFP level and liver function were sequentially tested during the median follow-up period of 7.5 months (range, 3-30), demonstrating that the median serum AFP level significantly decreased from 376.6 ng/ ml to 57.6 ng/ml (p$lt;0.05). With the decrease in serum AFP levels, serum levels of GOT and GPT also decreased (p$lt;0.01). In 20 out of 22 patients, serum level of AFP decreased to less than 50% of the inital level of AFP after the follow-up period. In eight and seven patients, serum levels of AFP decreased to the normal level, less than 20 ng/ml, after tile median follow-up period of 14.5 months (range, 5-30) and 20-49 ng/ml during 4.5 months (range, 3.11), respectively. In two patients, however, change in the serum AFP levels was not observed. In seven patients who had the initial serum AFP level of more than 100 ng/ml and tested serum AFP level and liver function test every two months. serum levels of AFP, GOT and GPT concurrently decreased during the follow-up period. These results demonstrating that serum AFP level increased in benign liver diseases, such as liver cirrhosis and chronic hepatitis, suggest that, in order to increase the clinical usefulness of serum level of AFP for the diagnosis of hepatocellular carcinoma, serum AFP level should be reevaluated for the specificity for hepatocellular carcinoma according to the cut-off value. Because serum AFP level decreased in most of the patients after the follow-up period, tit is also suggested that AFP elevated in benign liver disease might be different from that in hepatocellular carcinoma in molecular characteristics.

결절성 갑상선종을 동반한 선천성 간섬유증 1 예

김창민,이영현,장자준,홍원선,이진오,김유철,강태웅,강윤구,김서운,임영혁,김용조 대한내과학회 1994 대한내과학회지 Vol.47 No.1

Congenital hepatic fibrosis is a relatively rare disease which is characterized by bile ductular proliferation and prominent fibrosis in the portal area of liver resulting in portal hypertension. The patients usually present with esophageal varix bleeding or repeated episodes of acute cholangitis which both are the major determinants of the long-term prognosis. Congenital hepatic fibrosis is frequently associated with other abnormalities such as polycystic kidney, Caroli`s syndrome, cystic dysplasia of the pancreas, intestinal lymphangiectasia, pulmonary emphysema, hemangioma and cleft palate. We report here a case of congenital hepatic fibrosis associated with nodular nontoxic goiter, which has not been reported previously, pancytopenia due to hypersplenism and polycystic kidney in a 24-year-old female patients.